L
Larissa A. Meyer
Researcher at University of Texas MD Anderson Cancer Center
Publications - 179
Citations - 5559
Larissa A. Meyer is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 31, co-authored 138 publications receiving 4133 citations. Previous affiliations of Larissa A. Meyer include University of Texas Health Science Center at Houston & Harris Health System.
Papers
More filters
Journal ArticleDOI
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
Victor Abkevich,Kirsten Timms,Bryan T. Hennessy,Jennifer Potter,Mark S. Carey,Larissa A. Meyer,Karen Smith-McCune,Russell Broaddus,Karen H. Lu,Jian Chen,Thanh Tran,Dominic P. Williams,Diana Iliev,Srikanth Jammulapati,Lisa M. Fitzgerald,Thomas C. Krivak,Julie A. DeLoia,Alexander Gutin,Gordon B. Mills,Jerry S. Lanchbury +19 more
TL;DR: The HRD score appears capable of detecting homologous recombination defects regardless of aetiology or mechanism, which could facilitate the use of PARP inhibitors and platinum in breast, ovarian, and other cancers.
Journal ArticleDOI
Guidelines for pre- and intra-operative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations — Part I
Gregg Nelson,Alon D. Altman,Alpa M. Nick,Larissa A. Meyer,Pedro T. Ramirez,Chahin Achtari,J. Antrobus,Jeffrey Huang,Michael J. Scott,Lena Wijk,N. Acheson,Olle Ljungqvist,Sean C. Dowdy +12 more
TL;DR: This research presents a meta-analyses of the immune system’s response to infectious disease and its role in promoting social and economic well-being in eight countries over a 25-year period.
Journal ArticleDOI
Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations—2019 update
Gregg Nelson,Jamie N. Bakkum-Gamez,Eleftheria Kalogera,Gretchen E. Glaser,Alon D. Altman,Larissa A. Meyer,Jolyn S. Taylor,Maria D. Iniesta,Javier Lasala,Gabriel E. Mena,Michael J. Scott,Chelsia Gillis,Kevin M. Elias,Lena Wijk,Jeffrey Huang,Jonas Nygren,Olle Ljungqvist,Pedro T. Ramirez,Sean C. Dowdy +18 more
TL;DR: This is the first updated Enhanced Recovery After Surgery (ERAS) Society guideline presenting a consensus for optimal perioperative care in gynecologic/oncology surgery, and the updated evidence base and recommendation are presented.
Journal ArticleDOI
Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer
Bryan T. Hennessy,Kirsten Timms,Mark S. Carey,Alexander Gutin,Larissa A. Meyer,Darl D. Flake,Victor Abkevich,Jennifer Potter,Dmitry Pruss,Pat Glenn,Yang Li,Jie Li,Ana M. Gonzalez-Angulo,Karen K. Smith McCune,Maurie Markman,Russell Broaddus,Jerry S. Lanchbury,Karen H. Lu,Gordon B. Mills +18 more
TL;DR: BRCA(1/2) somatic and germline mutations and expression loss are sufficiently common in ovarian cancer to warrant assessment for prediction of benefit in clinical trials of PARP1 inhibitors.
Journal ArticleDOI
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
Alexi A. Wright,Kari Bohlke,Deborah K. Armstrong,Michael A. Bookman,William A. Cliby,Robert L. Coleman,Don S. Dizon,Joseph J. Kash,Larissa A. Meyer,Kathleen N. Moore,Alexander B. Olawaiye,Jessica Oldham,Ritu Salani,Dee Sparacio,William P. Tew,Ignace Vergote,Mitchell I. Edelson +16 more
TL;DR: For selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are noninferior to primary cytoreductive and adjuvant chemotherapy with respect to overall and progression-free survival and are associated with less perioperative morbidity and mortality.